The Mediterranean diet has what most popular diets lack: a large randomized trial. PREDIMED, run in Spain with 7,447 adults at high cardiovascular risk, found roughly a 30 percent relative reduction in major cardiovascular events — stroke, heart attack, cardiovascular death — among participants assigned to a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts, compared with a low-fat control, per results published in the New England Journal of Medicine in 2013 and corrected in 2018.
This site publishes information, not medical advice. Trial results here are attributed findings, not recommendations; people on anticoagulants, with diabetes, or with kidney disease should change their eating pattern only with their own clinician, because diet interacts with medication dosing.
What is the Mediterranean diet, concretely?
The pattern studied in the trials is specific: high olive oil as the principal fat, nuts daily, vegetables, legumes, and fruit at most meals, fish at least three times weekly, whole grains, moderate wine with meals for those who drank, and low intake of red meat, processed meat, butter, cream, sweets, and sugary drinks. PREDIMED scored adherence on a 14-point scale and enrolled participants whose scores were low at baseline. That definition matters because the trial evidence applies to this pattern as studied — olive-oil-based, fish-forward, plant-heavy — not to anything a restaurant or product line labels Mediterranean.
What did PREDIMED actually test and find?
PREDIMED randomized community-dwelling adults at high risk — diabetes, smoking, hypertension, or other risk factors — to one of three arms: Mediterranean diet plus free extra-virgin olive oil, Mediterranean diet plus free mixed nuts, or advice to follow a low-fat diet. Over a median follow-up of 4.8 years, both Mediterranean arms showed about 30 percent relative risk reduction in the primary composite endpoint, driven mostly by a lower stroke rate, per the 2013 report. In 2018 the journal republished the analysis with corrected randomization irregularities at two sites; the re-analysis reached substantially the same conclusions. The trial was stopped early at each arm's favorable result, a design feature that tends to inflate effect estimates, as the investigators themselves note.
The wider trial record
- Lyon Diet Heart Study, 1999: a secondary-prevention randomized trial in French heart-attack survivors found a 50 to 70 percent reduction in cardiac events on an alpha-linolenic-acid-enriched Mediterranean-style diet — a single trial, but among the largest diet effects in cardiology literature.
- PREDIMED, 2013/2018: primary prevention, ~7,447 participants, ~30 percent reduction in major cardiovascular events; strongest for stroke.
- PREDIMED substudies: improved blood pressure, lipid profiles, and inflammatory markers in the Mediterranean arms, per published analyses.
- Cohort evidence, including analyses of over 25,000 initially healthy US women reported in 2018 in JAMA Network Open: higher adherence associated with lower cardiovascular incidence, with anti-inflammatory and glucose-metabolism markers mediating part of the association.
A 30 percent reduction in events is a food-pattern effect size most drugs would envy — but it comes from one large trial in one country, stopped early, in high-risk adults.
Related stories: What studies actually show about ultra-processed foods and health outcomes · What the USPSTF says about vitamin D supplements for healthy adults.
Does the evidence generalize?
Partially, and the qualifications are specific. PREDIMED enrolled Spaniards aged 55 to 80 already at elevated cardiovascular risk, with free olive oil and nuts supplied — an adherence subsidy a real-world reader does not get. The Lyon trial tested a modified pattern in secondary prevention. Whether the full effect size transfers to lower-risk, younger, or non-Mediterranean populations has not been demonstrated by any trial of comparable size; cohort studies in other countries support direction but not magnitude. The 2020-2025 Dietary Guidelines list the Mediterranean-style pattern among the healthy eating patterns it endorses, which is the federal signal, but the guidelines stop short of promising the trial's event reduction to everyone.
What component carries the effect?
The trials were designed with composite interventions, so no component is isolated. The PREDIMED arms differed from control in the whole package, and substudy analyses attribute plausible roles to extra-virgin olive oil's polyphenols, the omega-3 fats in nuts and fish, and the pattern's high fiber. Trials of single components — omega-3 supplements, for instance, in the VITAL and other trials — have generally been disappointing, which suggests the pattern, not a pill extracted from it, is what the trials tested. Reviews in the field state this openly: the evidence supports the dietary pattern, and claims about one magic ingredient outrun the design.
How does it compare on weight and diabetes?
On diabetes, PREDIMED's own subanalysis found a roughly 40 percent reduction in new diabetes among the Mediterranean arms in a freely eating, calorie-unrestricted design — published in Annals of Internal Medicine in 2014, from the same corrected dataset. On weight, the Mediterranean arms in PREDIMED did not restrict calories and did not produce weight loss; long-term trials show Mediterranean-style patterns perform comparably to low-fat and low-carbohydrate approaches for weight, per meta-analyses summarized by professional societies. Readers expecting the trial benefits to include slimming are reading a claim the trials did not make.
What does it cost, and who struggles to follow it?
The trial supplied its key foods free, and real-world adherence is the weak link: fish, nuts, and olive oil are expense lines in a food budget that processed staples do not carry, which is why food-access researchers treat Mediterranean-diet adherence as partly an income variable. In PREDIMED itself, adherence scores rose in all three arms, including control — an effect of intensive dietary counseling that any reader translating the trial into life should account for. Anyone considering the switch while managing cardiovascular disease is making a treatment decision that belongs with their own clinician, particularly if anticoagulants, diuretics, or glucose-lowering medications are in the picture, since a large dietary change can shift drug requirements.